← Back to Search

Interferon

Interferon Alfa With/Without Vaccine for Skin Cancer

Phase 3
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No autoimmune disease (e.g., systemic lupus erythematosus, multiple sclerosis, ankylosing spondylitis)
Creatinine clearance at least 40 mL/min
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is comparing the effectiveness of two treatments for metastatic melanoma. One treatment is interferon alfa alone, and the other is interferon alfa combined with vaccine therapy.

Who is the study for?
This trial is for adults with metastatic melanoma, who have no severe psychiatric disorders or autoimmune diseases, and whose major organs are functioning well. Women must use effective contraception, and participants should not have had certain treatments like interferon alfa or vaccines for melanoma within the past year.Check my eligibility
What is being tested?
The study is testing whether combining a melanoma vaccine with interferon alfa improves treatment outcomes compared to using interferon alfa alone in patients with spreading skin cancer. Participants will be randomly assigned to one of the two treatment groups.See study design
What are the potential side effects?
Interferon alfa can cause flu-like symptoms, fatigue, decreased appetite, and low blood counts. The vaccine may trigger injection site reactions and mild flu-like symptoms. Both treatments could potentially lead to an increased immune response causing discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have an autoimmune disease.
Select...
My kidneys are working well enough (creatinine clearance is 40 mL/min or more).
Select...
My melanoma has spread to other parts of my body.
Select...
My heart can pump blood effectively without failure.
Select...
I have no other cancers except for non-melanoma skin cancer.
Select...
I do not have any heart rhythm problems that cause symptoms.
Select...
I do not have unstable chest pain.
Select...
I am 18 years old or older.
Select...
My thyroid condition is controlled with medication.
Select...
It has been over 4 months since my last adjuvant therapy.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,750 Previous Clinical Trials
8,067,152 Total Patients Enrolled
Kenneth B. Von Eschen, PhDStudy ChairGlaxoSmithKline

Media Library

Interferon Alfa (Interferon) Clinical Trial Eligibility Overview. Trial Name: NCT00002767 — Phase 3
Skin Cancer Research Study Groups:
Skin Cancer Clinical Trial 2023: Interferon Alfa Highlights & Side Effects. Trial Name: NCT00002767 — Phase 3
Interferon Alfa (Interferon) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002767 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do many hospitals in Canada have this trial available to patients?

"Currently, this clinical trial is underway at 4 locations- University of Alabama Comprehensive Cancer Center in Birmingham, Alabama, Kaiser Permanente Medical Center-Sacramento in Sacramento, California, Adventist Health System/Sunbelt, Inc. in Orlando, Florida, and 27 other sites."

Answered by AI

Are there opportunities for more patients to join this trial?

"No, this study is no longer recruiting patients according to the latest information found on clinicaltrials.gov. This study was first posted on 1/1/1996 but was last updated on 1/3/2014. There are, however, 784 other clinical trials that are actively recruiting right now."

Answered by AI

Is this medication able to be legally prescribed in the United States?

"This treatment received a safety score of 3 because it is a Phase 3 trial. This indicates that while there is data supporting the efficacy of the treatment, there are also multiple rounds of data supporting safety."

Answered by AI

Who else is applying?

What site did they apply to?
Oregon Cancer Center at Oregon Health Sciences University
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

ive tried three different immunotherapies and im hoping this can help.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
1996. "Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002767.
All > Ic
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top